KDR and neoplasm: We found that a lower pre-treatment blood neutrophil-to-lymphocyte ratio (n=4, HR 0.37, 95%CI 0.21–0.67) predicts good prognosis, higher tumor mutation burden (n=10, OR 4.83, 95%CI 2.16–10.78) predicts response to ICIs, and liver metastasis (n=16, OR 0.32, 95%CI 0.16–0.63) indicates resistance to ICIs, especially when combined with VEGFR inhibitors.